Parathyroid hormone - A bone anabolic and catabolic agent

Current Opinion in Pharmacology

Volumn 5, Issue 6 SPEC. ISS., 2005, Pages 612-617

  Poole, Kenneth E S ^a   Reeve, Jonathan ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCIUM; CALCIUM SENSING RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE RECEPTOR; PARATHYROID HORMONE RELATED PROTEIN RECEPTOR; PARATHYROID HORMONE[1-34]; PLASMID VECTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

BONE METABOLISM; BONE REMODELING; BONE TURNOVER; CALCIUM HOMEOSTASIS; CLINICAL TRIAL; DNA MICROARRAY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; HORMONAL REGULATION; HORMONE STRUCTURE; HUMAN; HYPERCALCEMIA; NONHUMAN; NONVIRAL GENE THERAPY; OSTEOBLAST; OSTEOCYTE; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK REDUCTION; SECONDARY HYPERPARATHYROIDISM; VERTEBRA FRACTURE;

EID: 27744497818     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2005.07.004     Document Type: Review

References (63)

1. T.J. Aspray L. Yan A. Prentice Parathyroid hormone and rates of bone formation are raised in perimenopausal rural Gambian women Bone 36 2005 710-720
2. L. Yan B. Zhou X. Wang S. D'Ath A. Laidlaw M.A. Laskey A. Prentice Older people in China and the United Kingdom differ in the relationships among parathyroid hormone, vitamin D, and bone mineral status Bone 33 2003 620-627
3. M. Gowen G.B. Stroup R.A. Dodds I.E. James B.J. Votta B.R. Smith P.K. Bhatnagar A.M. Lago J.F. Callahan E.G. DelMar et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats J Clin Invest 105 2000 1595-1604
4. S.J. Steddon J. Cunningham Calcimimetics and calcilytics-fooling the calcium receptor Lancet 365 2005 2237-2239
5. W.F. Schwindinger J. Fredericks L. Watkins H. Robinson J.M. Bathon M. Pines L.J. Suva M.A. Levine Coupling of the PTH/PTHrP receptor to multiple G-proteins. Direct demonstration of receptor activation of Gs, Gq/11, and Gi(1) by [alpha-32P]GTP-gamma-azidoanilide photoaffinity labeling Endocrine 8 1998 201-209
6. R. Cheung M.S. Erclik J. Mitchell Increased expression of G(11)alpha in osteoblastic cells enhances parathyroid hormone activation of phospholipase C and AP-1 regulation of matrix metalloproteinase-13 mRNA J Cell Physiol 204 2005 336-343
7. H. Kondo J. Guo F.R. Bringhurst Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells J Bone Miner Res 17 2002 1667-1679
8. F.R. Bringhurst PTH receptors and apoptosis in osteocytes J Musculoskelet Neuronal Interact 2 2002 245-251
9. L. Nguyen-Yamamoto L. Rousseau J.H. Brossard R. Lepage P. D'Amour Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor Endocrinology 142 2001 1386-1392
10. M.K. Sutherland L.G. Rao J.N. Wylie A. Gupta H. Ly J. Sodek T.M. Murray Carboxyl-terminal parathyroid hormone peptide (53-84) elevates alkaline phosphatase and osteocalcin mRNA levels in SaOS-2 cells J Bone Miner Res 9 1994 453-458
11. P. Divieti N. Inomata K. Chapin R. Singh H. Juppner F.R. Bringhurst Receptors for the carboxyl-terminal region of pth(1-84) are highly expressed in osteocytic cells Endocrinology 142 2001 916-925
12. E.M. Brown G. Gamba D. Riccardi M. Lombardi R. Butters O. Kifor A. Sun M.A. Hediger J. Lytton S.C. Hebert Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid Nature 366 1993 575-580
13. E.M. Brown R.J. MacLeod Extracellular calcium sensing and extracellular calcium signaling Physiol Rev 81 2001 239-297
14. 2+ in bovine parathyroid cells evoked by extracellular divalent cations. Evidence for a cell surface calcium receptor J Biol Chem 262 1987 5188-5196
15. M. Peacock J.P. Bilezikian P.S. Klassen M.D. Guo S.A. Turner D. Shoback Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism J Clin Endocrinol Metab 90 2005 135-141
16. C. Charytan J.W. Coburn M. Chonchol J. Herman Y.H. Lien W. Liu P.S. Klassen L.C. McCary V. Pichette Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis Am J Kidney Dis 46 2005 58-67
17. M.R. Pollak E.M. Brown Y.H. Chou S.C. Hebert S.J. Marx B. Steinmann T. Levi C.E. Seidman J.G. Seidman Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism Cell 75 1993 1297-1303
18. M.R. Pollak Y.H. Chou S.J. Marx B. Steinmann D.E. Cole M.L. Brandi S.E. Papapoulos F.H. Menko G.N. Hendy E.M. Brown et al. Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Effects of mutant gene dosage on phenotype J Clin Invest 93 1994 1108-1112
19. A.B. Hodsman D.A. Hanley M.P. Ettinger M.A. Bolognese J. Fox A.J. Metcalfe R. Lindsay Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis J Clin Endocrinol Metab 88 2003 5212-5220
20. A.B. Hodsman L.J. Fraher T. Ostbye J.D. Adachi B.M. Steer An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis J Clin Invest 91 1993 1138-1148
21. A.B. Hodsman B.M. Steer Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: Evidence for de novo bone formation on quiescent cancellous surfaces Bone 14 1993 523-527
22. J.N. Bradbeer M.E. Arlot P.J. Meunier J. Reeve Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and oestrogen: Increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone Clin Endocrinol (Oxf) 37 1992 282-289
23. Y. Jiang J.J. Zhao B.H. Mitlak O. Wang H.K. Genant E.F. Eriksen Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure J Bone Miner Res 18 2003 1932-1941
24. A.B. Hodsman M. Kisiel J.D. Adachi L.J. Fraher P.H. Watson Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis Bone 27 2000 311-318
25. D.W. Dempster F. Cosman E.S. Kurland H. Zhou J. Nieves L. Woelfert E. Shane K. Plavetic R. Muller J. Bilezikian et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study J Bone Miner Res 16 2001 1846-1853
26. H. Oxlund C. Ejersted T.T. Andreassen O. Torring M.H. Nilsson Parathyroid hormone (1-34) and (1-84) stimulate cortical bone formation both from periosteum and endosteum Calcif Tissue Int 53 1993 394-399
27. J.R. Zanchetta C.E. Bogado J.L. Ferretti O. Wang M.G. Wilson M. Sato G.A. Gaich G.P. Dalsky S.L. Myers Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis J Bone Miner Res 18 2003 539-543
28. K. Uusi-Rasi L.M. Semanick J.R. Zanchetta C.E. Bogado E.F. Eriksen M. Sato T.J. Beck Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women Bone 36 2005 948-958
29. L. Qin P. Qiu L. Wang X. Li J.T. Swarthout P. Soteropoulos P. Tolias N.C. Partridge Gene expression profiles and transcription factors involved in parathyroid hormone signaling in osteoblasts revealed by microarray and bioinformatics J Biol Chem 278 2003 19723-19731
30. J.E. Onyia L.M. Helvering L. Gelbert T. Wei S. Huang P. Chen E.R. Dow A. Maran M. Zhang S. Lotinun et al. Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: An analysis by DNA microarray J Cell Biochem 95 2005 403-418
31. V. Krishnan T.L. Moore Y.L. Ma L.M. Helvering C.A. Frolik K.M. Valasek P. Ducy A.G. Geiser Parathyroid hormone bone anabolic action requires Cbfa1/Runx2-dependent signaling Mol Endocrinol 17 2003 423-435
32. B. Demiralp H.L. Chen A.J. Koh E.T. Keller L.K. McCauley Anabolic actions of parathyroid hormone during bone growth are dependent on c-fos Endocrinology 143 2002 4038-4047
33. T. Ishizuya S. Yokose M. Hori T. Noda T. Suda S. Yoshiki A. Yamaguchi Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells J Clin Invest 99 1997 2961-2970
34. E. Canalis M. Centrella W. Burch T.L. McCarthy Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures J Clin Invest 83 1989 60-65
35. R.M. Locklin S. Khosla R.T. Turner B.L. Riggs Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone J Cell Biochem 89 2003 180-190
36. P. Watson D. Lazowski V. Han L. Fraher B. Steer A. Hodsman Parathyroid hormone restores bone mass and enhances osteoblast insulin-like growth factor I gene expression in ovariectomized rats Bone 16 1995 357-365
37. D.D. Bikle T. Sakata C. Leary H. Elalieh D. Ginzinger C.J. Rosen W. Beamer S. Majumdar B.P. Halloran Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone J Bone Miner Res 17 2002 1570-1578
38. R.L. Jilka R.S. Weinstein T. Bellido P. Roberson A.M. Parfitt S.C. Manolagas Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone J Clin Invest 104 1999 439-446
39. H. Dobnig R.T. Turner Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells Endocrinology 136 1995 3632-3638
40. D. Leaffer M. Sweeney L.A. Kellerman Z. Avnur J.L. Krstenansky B.H. Vickery J.P. Caulfield Modulation of osteogenic cell ultrastructure by RS-23581, an analog of human parathyroid hormone (PTH)-related peptide-(1-34), and bovine PTH-(1-34) Endocrinology 136 1995 3624-3631
41. A.M. Parfitt Parathyroid hormone and periosteal bone expansion J Bone Miner Res 17 2002 1741-1743
42. H. Keller M. Kneissel SOST is a target gene for PTH in bone Bone 37 2005 148-158
43. K.E.S. Poole R.L. van Bezooijen N. Loveridge H. Hamersma S. Papapoulos C.W. Lowik J. Reeve Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation FASEB J 2005 [doi: 10.1096/ fj.05-4221fje]
44. C.A. Frolik E.C. Black R.L. Cain J.H. Satterwhite P.L. Brown-Augsburger M. Sato J.M. Hock Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure Bone 33 2003 372-379
45. Y.L. Ma R.L. Cain D.L. Halladay X. Yang Q. Zeng R.R. Miles S. Chandrasekhar T.J. Martin J.E. Onyia Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation Endocrinology 142 2001 4047-4054
46. A.B. Hodsman B.M. Steer L.J. Fraher D.J. Drost Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients Bone Miner 14 1991 67-83
47. A.F. Stewart PTHrP(1-36) as a skeletal anabolic agent for the treatment of osteoporosis Bone 19 1996 303-306
48. J. Bonadio E. Smiley P. Patil S. Goldstein Localized, direct plasmid gene delivery in vivo: Prolonged therapy results in reproducible tissue regeneration Nat Med 5 1999 753-759
49. J. Reeve R. Hesp D. Williams P. Hulme L. Klenerman J.M. Zanelli A.J. Darby G.W. Tregear J.A. Parsons Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis Lancet 1 1976 1035-1038
50. J. Reeve P.J. Meunier J.A. Parsons M. Bernat O.L. Bijvoet P. Courpron C. Edouard L. Klenerman R.M. Neer J.C. Renier et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: A multicentre trial Br Med J 280 1980 1340-1344
51. R.M. Neer C.D. Arnaud J.R. Zanchetta R. Prince G.A. Gaich J.Y. Reginster A.B. Hodsman E.F. Eriksen S. Ish-Shalom H.K. Genant et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 2001 1434-1441
52. R. Marcus O. Wang J. Satterwhite B. Mitlak The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis J Bone Miner Res 18 2003 18-23
53. E.S. Orwoll W.H. Scheele S. Paul S. Adami U. Syversen A. Diez-Perez J.M. Kaufman A.D. Clancy G.A. Gaich The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis J Bone Miner Res 18 2003 9-17
54. National Institute for Clinical Excellence Technology Appraisal 87: Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. 2005 [URL: http://www.nice.org.uk/pdf/TA087guidance.pdf].
55. F. Cosman J. Nieves L. Woelfert V. Shen R. Lindsay Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women J Bone Miner Res 13 1998 1051-1055
56. J.S. Finkelstein A. Hayes J.L. Hunzelman J.J. Wyland H. Lee R.M. Neer The effects of parathyroid hormone, alendronate, or both in men with osteoporosis N Engl J Med 349 2003 1216-1226
57. B. Ettinger J. San Martin G. Crans I. Pavo Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate J Bone Miner Res 19 2004 745-751
58. D.M. Black S.L. Greenspan K.E. Ensrud L. Palermo J.A. McGowan T.F. Lang P. Garnero M.L. Bouxsein J.P. Bilezikian C.J. Rosen The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis N Engl J Med 349 2003 1207-1215
59. R. Lindsay W.H. Scheele R. Neer G. Pohl S. Adami C. Mautalen J.Y. Reginster J.J. Stepan S.L. Myers B.H. Mitlak Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis Arch Intern Med 164 2004 2024-2030
60. E.S. Kurland S.L. Heller B. Diamond D.J. McMahon F. Cosman J.P. Bilezikian The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)] Osteoporos Int 15 2004 992-997
61. D.M. Black C.J. Rosen L. Palermo T. Hue K.E. Ensrud S.L. Greenspan T.F. Lang J.A. McGowen J.P. Bilezikian The effect of 1 year of alendronate following 1 year of PTH (PTH1-84): Second year results from the PTH and alendronate (PaTH) trial [abstract] Bone 36 2005 S448-S449
62. R.S. Rittmaster M. Bolognese M.P. Ettinger D.A. Hanley A.B. Hodsman D.L. Kendler C.J. Rosen Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate J Clin Endocrinol Metab 85 2000 2129-2134
63. T. Bellido A.A. Ali I. Gubrij L.I. Plotkin Q. Fu C.A. O'Brien Chronic elevation of PTH in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis Endocrinology 2005 [Hoi:10.1210/en.2005-0239; URL: http://endo.endojournals.org/cgi/rapidpdf/en.2005-0239v1]